<DOC>
	<DOCNO>NCT00268528</DOCNO>
	<brief_summary>This clinical trial assess compliance long-term mercaptopurine treatment young patient acute lymphoblastic leukemia remission . Assessing young patient acute lymphoblastic leukemia may take medication prescribe may help identify way assist take medication consistently may improve long-term treatment outcome .</brief_summary>
	<brief_title>Study Assess Compliance With Long-Term Mercaptopurine Treatment Young Patients With Acute Lymphoblastic Leukemia Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine compare adherence maintenance mercaptopurine use follow assessment : serial red cell mercaptopurine metabolite ( i.e. , 6TGN methylTIMP ) , frequency mercaptopurine dose use electronic pill monitor system ( MEMS® ) , self-report adherence mercaptopurine questionnaire cohort young patient acute lymphoblastic leukemia first remission belong four different ethnic racial group ( Caucasians , African-Americans , Hispanics , Asians ) . II . Determine impact adherence mercaptopurine event-free-survival ( EFS ) entire cohort , adjust know predictor disease outcome . III . Define critical level adherence significant impact EFS entire cohort . IV . Describe prevalence adherence mercaptopurine ethnicity . V. Describe behavioral sociodemographic predictor adherence . VI . Describe pill-taking practice cohort . VII . Evaluate impact adherence ethnic/racial difference EFS . SECONDARY OBJECTIVES : I. Assess concordance among 6TGN methylTIMP level , electronic pill monitoring , self-reported adherence ethnic/racial group . OUTLINE : This multicenter study . Patients receive electronic pill monitor system comprise empty MEMS® medication bottle TrackCap™ child resistant ( CR ) . The mercaptopurine prescription fill use system . Beginning day 1 third later course maintenance therapy , patient take dos mercaptopurine MEMS® medication bottle TrackCap™ CR least 6 month . The MEMS® TrackCap™ CR mail study center end study . Patients also receive oral methotrexate indicate individual chemotherapy regimen . NOTE : *Study close accrual Caucasian Hispanic patient 8/14/2009 . Blood sample collect day 1 , 29 , 57 , 85 , 113 , 141 , 169 . Patient caregiver complete demographic questionnaire day 29 . Patient and/or caregiver complete self-reported adherence questionnaire day 29 , 57 , 113 , 141 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia ( ALL ) ≤ 21 year age Disease first remission Receiving self parent/caregiveradministered oral antimetabolite chemotherapy maintenance phase therapy Has complete least two courses* maintenance chemotherapy , schedule receive least two planned course maintenance chemotherapy Treatment plan must include oral mercaptopurine ( 6MP ) 75 mg/m^2/day oral methotrexate 20 mg/m^2/week maintenance phase Dose modification 6MP methotrexate base laboratory clinical parameter acceptable Belongs one four follow ethnic/racial category : AfricanAmerican , Asian , Caucasian* , Hispanic* Concurrent enrollment another therapeutic study ALL allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>